An Orally Antitumor Chalcone Hybrid Inhibited HepG2 Cells Growth and Migration As the Tubulin Binding Agent

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2019 Feb 12

PMID 30740631

Citations 10

Authors

Wang Yan

Chen Xiangyu

Li Ya

Wang Yu

Xu Feng

Affiliations

Soon will be listed here.

Abstract

Liver cancer is a kind of high mortality cancer due to the difficulty of early diagnosis. It is necessary to develop the anticancer agents to treat liver cancer. Here, a novel chalcone derivative was synthesized and evaluated for anticancer activity in vitro against liver cancer cell lines (HepG2, SNU-423, SMMC7221, and SNU-398). The chalcone hybrid 9 displayed the antiproliferative effect against HepG2, SNU-423, SMMC7221 and SNU-398 cells with IC values of 0.9 μM, 2.7 μM, 6.2 μM and 4.6 μM, respectively. Cellular mechanisms showed that derivative 9 could obviously inhibit HepG2 cells growth and colony formation in a concentration-dependent manner. Analogue 9 inhibited the migration by regulating the expression levels of migration-releated markers and transcription factors (Snail and Slug). Tubulin polymerization inhibition assay illustrated that chalcone hybrid 9 might be a potent tubulin polymerization inhibitor. Importantly, compound 9 displayed the antitumor activity against liver cancer HepG2 cells in vivo with the low toxicity toward mice. Therefore, compound 9 as a novel tubulin polymerization inhibitor deserves further investigation to treat liver cancer. Graphical abstract Compound 9 displayed the antitumor activity against liver cancer HepG2 cells in vivo and low toxicity toward mice Figure: Orally antitumor chalcone hybrid 9 inhibited HepG2 cells growth and migration as the tubulin binding agent.

Citing Articles

The Proapoptotic Effect of MB-653 Is Associated with the Modulation of Metastasis and Invasiveness-Related Signalling Pathways in Human Colorectal Cancer Cells.

Sokoli L, Takac P, Budovska M, Michalkova R, Kello M, Nosalova N Biomolecules. 2025; 15(1).

PMID: 39858466 PMC: 11762530. DOI: 10.3390/biom15010072.

Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents.

Sflakidou E, Leonidis G, Foroglou E, Siokatas C, Sarli V Molecules. 2022; 27(19).

PMID: 36235168 PMC: 9572494. DOI: 10.3390/molecules27196632.

Two Important Anticancer Mechanisms of Natural and Synthetic Chalcones.

Constantinescu T, Mihis A Int J Mol Sci. 2022; 23(19).

PMID: 36232899 PMC: 9570335. DOI: 10.3390/ijms231911595.

New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization.

Mohammed H, Abd El-Hafeez A, Ebeid K, Mekkawy A, Abourehab M, Wafa E J Enzyme Inhib Med Chem. 2022; 37(1):1346-1363.

PMID: 35548854 PMC: 9116245. DOI: 10.1080/14756366.2022.2072308.

FAM172A affects cell proliferation and apoptosis not by targeting β-tubulin in HepG2 cells.

Xu A, He C, Tuerxun Z, Anikezi A Transl Cancer Res. 2022; 9(9):5637-5644.

PMID: 35117927 PMC: 8797783. DOI: 10.21037/tcr-20-2868.

References

Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K . CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther. 2004; 3(1):29-37. View

Teng I, Tsai M, Shih S, Tsuei B, Chang H, Chuang Y . Chalcone Derivatives Enhance ATP-Binding Cassette Transporters A1 in Human THP-1 Macrophages. Molecules. 2018; 23(7). PMC: 6100038. DOI: 10.3390/molecules23071620. View

Huang X, Shen Q, Zhang H, Li J, Tian Y, Quan Z . Design and Synthesis of Novel Dehydroepiandrosterone Analogues as Potent Antiproliferative Agents. Molecules. 2018; 23(9). PMC: 6225165. DOI: 10.3390/molecules23092243. View

Szliszka E, Czuba Z, Mazur B, Paradysz A, Krol W . Chalcones and dihydrochalcones augment TRAIL-mediated apoptosis in prostate cancer cells. Molecules. 2010; 15(8):5336-53. PMC: 6257745. DOI: 10.3390/molecules15085336. View

Chang T, More S, Lu I, Hsu J, Chen T, Jen Y . Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro. Eur J Med Chem. 2011; 46(9):3810-9. DOI: 10.1016/j.ejmech.2011.05.049. View

Crous-Maso J, Palomeras S, Relat J, Camo C, Martinez-Garza U, Planas M . (-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer. Molecules. 2018; 23(5). PMC: 6099607. DOI: 10.3390/molecules23051160. View

Saxena H, Faridi U, Kumar J, Luqman S, Darokar M, Shanker K . Synthesis of chalcone derivatives on steroidal framework and their anticancer activities. Steroids. 2007; 72(13):892-900. DOI: 10.1016/j.steroids.2007.07.012. View

Chen H, Lin Z, Arnst K, Miller D, Li W . Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2017; 22(8). PMC: 6152078. DOI: 10.3390/molecules22081281. View

Zhang X, Zhang S, Sun Q, Jiao W, Yan Y, Zhang X . Compound K Induces Endoplasmic Reticulum Stress and Apoptosis in Human Liver Cancer Cells by Regulating STAT3. Molecules. 2018; 23(6). PMC: 6099685. DOI: 10.3390/molecules23061482. View

10.

Li L, Su N, Zhou T, Zheng D, Wang Z, Chen H . Mixed lineage kinase ZAK promotes epithelial-mesenchymal transition in cancer progression. Cell Death Dis. 2018; 9(2):143. PMC: 5833348. DOI: 10.1038/s41419-017-0161-x. View

11.

Piscaglia F, Ogasawara S . Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer. 2018; 7(1):104-119. PMC: 5892363. DOI: 10.1159/000485471. View

12.

Cevallos R, Rodriguez-Martinez G, Gazarian K . Wnt/β-Catenin/TCF Pathway Is a Phase-Dependent Promoter of Colony Formation and Mesendodermal Differentiation During Human Somatic Cell Reprogramming. Stem Cells. 2018; 36(5):683-695. DOI: 10.1002/stem.2788. View

13.

Rampa A, Bartolini M, Pruccoli L, Naldi M, Iriepa I, Moraleda I . Exploiting the Chalcone Scaffold to Develop Multifunctional Agents for Alzheimer's Disease. Molecules. 2018; 23(8). PMC: 6222323. DOI: 10.3390/molecules23081902. View

14.

Barbosa T, Sousa S, Amorim F, Rodrigues Y, de Assis P, Caldas J . Design, synthesis and antileishmanial in vitro activity of new series of chalcones-like compounds: a molecular hybridization approach. Bioorg Med Chem. 2011; 19(14):4250-6. DOI: 10.1016/j.bmc.2011.05.055. View

15.

Kamal A, Prabhakar S, Ramaiah M, Reddy P, Reddy C, Mallareddy A . Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers. Eur J Med Chem. 2011; 46(9):3820-31. DOI: 10.1016/j.ejmech.2011.05.050. View

16.

Said R, Kurzrock R, Naing A, Hong D, Fu S, Piha-Paul S . Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs. 2015; 33(4):911-20. PMC: 4492845. DOI: 10.1007/s10637-015-0251-5. View

17.

Delord J, Ravaud A, Bennouna J, Fumoleau P, Favrel S, Pinel M . Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. Invest New Drugs. 2012; 31(3):724-33. DOI: 10.1007/s10637-012-9878-7. View

18.

Yan J, Chen J, Zhang S, Hu J, Huang L, Li X . Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo. J Med Chem. 2016; 59(11):5264-83. DOI: 10.1021/acs.jmedchem.6b00021. View

19.

Kakwani M, Suryavanshi P, Ray M, Rajan M, Majee S, Samad A . Design, synthesis and antimycobacterial activity of cinnamide derivatives: a molecular hybridization approach. Bioorg Med Chem Lett. 2011; 21(7):1997-9. DOI: 10.1016/j.bmcl.2011.02.022. View

20.

Ozdemir A, Sever B, Altintop M, Kaya Tilki E, Dikmen M . Design, Synthesis, and Neuroprotective Effects of a Series of Pyrazolines against 6-Hydroxydopamine-Induced Oxidative Stress. Molecules. 2018; 23(9). PMC: 6225304. DOI: 10.3390/molecules23092151. View